A Phase 1, First-in-Human Study of CITY-RBP4 in Healthy Volunteers and STGD1 Participants
A Phase 1, Randomized, Double-Masked, Placebo-Controlled, Single-Ascending and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CITY-RBP4 Administered Subcutaneously in Healthy Volunteers and Participants With Stargardt Disease Type 1 (STGD1)
This is a first-in-human (FIH), multicenter, randomized, double-masked, placebo-controlled adaptive clinical study evaluating the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) of CITY-RBP4, following single-ascending doses and multiple doses, via subcutaneous (SC) administration.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
The study consists of 3 sequential parts:
- Part A: Single-ascending doses in healthy volunteers
- Part B: Single-ascending doses in participants with Stargardt Disease Type 1 (STGD1)
- Part C: Multiple doses in participants with Stargardt Disease Type 1 (STGD1)
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 1단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: City Therapeutics
- 전화번호: 857-219-5440
- 이메일: clinicaltrials@citytx.com
연구 장소
-
-
Victoria
-
Melbourne, Victoria, 호주, 3004
- 모병
- Nucleus Network
-
연락하다:
- Nucleus Network Melbourne
- 전화번호: +61-1800-243-733
- 이메일: melbourne@nucleusnetwork.com
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Key Inclusion Criteria (Part A):
- Willing and able to provide written informed consent form
- Be aged 18 to 45 years (inclusive) at the time of signing the informed consent form
- Generally healthy on medical history, exam, labs, and ECG
- BCVA 20/25 or better in each eye
- Serum retinol above protocol threshold
- Body weight ≥40 kg and BMI of 18.0 to 32.0 kg/m2
- Men and WOCBP must agree to use highly effective methods of contraception or practice abstinence from 30 days before the first dose of CITY-RBP4, throughout the study, and for at least 180 days after treatment with CITY-RBP4 or the last study visit, whichever is longer; men must refrain from donating or banking sperm during the same period
- Female participants who are not WOCBP should meet at least 1 of the following criteria: have undergone a documented hysterectomy, bilateral oophorectomy, and/or bilateral salpingectomy; have medically confirmed ovarian failure, or achieved postmenopausal status
Key Exclusion Criteria (Part A):
- Clinically significant ocular disease or prior ocular surgery that could interfere with safety assessments
- History of vitamin A deficiency, malabsorption, or chronic diarrhea
- Clinically significant cardiac, hepatic, renal, pulmonary, neurologic, or psychiatric disease
- Positive hepatitis B, hepatitis C, or HIV screening
- Prior RNAi/oligonucleotide therapy or recent investigational treatment
- Recent vitamin A-related supplements, retinoids, or medications affecting vitamin A metabolism
- Pregnancy or breastfeeding, if applicable
Key Inclusion Criteria (Parts B and C)
- Participants aged 12 to 45 years
- Clinical diagnosis of STGD1 with documented ABCA4 pathogenic/likely pathogenic variant
- Minimum BCVA is required in the study eye
- Subjects must have a defined aggregate atrophic lesion in 1 or both eyes
- Body weight ≥40 kg
- Able to complete key ophthalmic safety assessments and comply with study precautions
Key Exclusion Criteria (Parts B and C)
- Ocular conditions that could confound retinal imaging or safety evaluation
- Prior ocular gene therapy, stem cell therapy, or retinal implant
- Vitamin A deficiency or recent prohibited vitamin A-related treatments
- Recent interventional study participation
- Clinically significant non-ophthalmic disease, abnormal screening labs/ECG, or positive hepatitis B, hepatitis C, or HIV screening
- Pregnancy or breastfeeding, if applicable
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 순차적 할당
- 마스킹: 더블
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
위약 비교기: 건강한 성인 대상자 (파트 A)
|
Saline (subcutaneous injection) |
|
실험적: CITY-RBP4 in Healthy Adults (Part A)
|
siRNA (subcutaneous injection) |
|
실험적: CITY-RBP4 in Participants with STGD1 (Parts B & C)
|
siRNA (subcutaneous injection) |
|
위약 비교기: In Participants with STGD1 (Parts B & C)
|
Saline (subcutaneous injection) |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Incidence, severity, and relationship of treatment-emergent adverse events (TEAEs)
기간: Through study completion, up to Day 360
|
To evaluate the safety and tolerability of single and multiple doses of CITY-RBP4 in healthy adults and participants with Stargardt disease Type 1 (STGD1) |
Through study completion, up to Day 360
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Plasma concentrations of CITY-RBP4
기간: Day 1 to Day 2
|
To characterize the pharmacokinetic (PK) profile of CITY-RBP4 after single and multiple doses of CITY-RBP4 in healthy adults and participants with STGD1 |
Day 1 to Day 2
|
|
Urine concentrations of CITY-RBP4
기간: Part A and B only: Day 1 to Day 2
|
To characterize the pharmacokinetic (PK) profile of CITY-RBP4 after a single dose of CITY-RBP4 in healthy adults and participants with STGD1 |
Part A and B only: Day 1 to Day 2
|
|
Maximum plasma concentration (Cmax)
기간: Day 1 to Day 2
|
To characterize the pharmacokinetic (PK) profile of CITY-RBP4 after single and multiple doses of CITY-RBP4 in healthy adults and participants with STGD1 |
Day 1 to Day 2
|
|
Time to maximum plasma concentration (Tmax)
기간: Day 1 to Day 2
|
To characterize the pharmacokinetic (PK) profile of CITY-RBP4 after single and multiple doses of CITY-RBP4 in healthy adults and participants with STGD1 |
Day 1 to Day 2
|
|
Area under plasma concentration-time curve (AUC)
기간: Day 1 to Day 2
|
To characterize the pharmacokinetic (PK) profile of CITY-RBP4 after single and multiple doses of CITY-RBP4 in healthy adults and participants with STGD1 |
Day 1 to Day 2
|
|
Terminal elimination half-life (t1/2)
기간: Day 1 to Day 2
|
To characterize the pharmacokinetic (PK) profile of CITY-RBP4 after single and multiple doses of CITY-RBP4 in healthy adults and participants with STGD1 |
Day 1 to Day 2
|
|
Apparent clearance (CL/F)
기간: Day 1 to Day 2
|
To characterize the pharmacokinetic (PK) profile of CITY-RBP4 after single and multiple doses of CITY-RBP4 in healthy adults and participants with STGD1 |
Day 1 to Day 2
|
|
Amount excreted unchanged (Ae)
기간: Part A and B only: Day 1 to Day 2
|
To characterize the pharmacokinetic (PK) profile of CITY-RBP4 after a single dose of CITY-RBP4 in healthy adults and participants with STGD1 |
Part A and B only: Day 1 to Day 2
|
|
Change from baseline in plasma RBP4 concentrations
기간: Up to Day 360
|
evaluate the pharmacodynamic (PD) effects of CITY-RBP4 on plasma retinol-binding protein 4 (RBP4) levels after single and multiple doses of CITY-RBP4 in healthy adults and participants with STGD1 |
Up to Day 360
|
|
Change from baseline in serum retinol concentrations
기간: Up to Day 360
|
To evaluate the pharmacodynamic (PD) effects of CITY-RBP4 on serum retinol levels after single and multiple doses of CITY-RBP4 in healthy adults and participants with STGD1 |
Up to Day 360
|
공동 작업자 및 조사자
수사관
수사관
- 연구 책임자: Medical Director, City Therapeutics
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
기타 연구 ID 번호
- CITY-RBP4-01
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .